A class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of purchasers of the common stock of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) in the Company's secondary public offering ("Secondary Offering") on or about January 21, 2010. According to the complaint, on or about January 21, 2010, the Registration Statement (the "Registration Statement") with respect to the Secondary Offering became effective and 3.6 million shares of AMAG common stock were sold to the public at $48.25 per share, thereby raising more than $173 million.

The complaint alleges that the Registration Statement failed to disclose that users of the Company's primary drug, Feraheme, had suffered adverse reactions, some requiring hospitalization. On February 4, 2010, Carol Werther, a Summer Street analyst downgraded AMAG from buy to neutral. In a note to clients she wrote, "We are aware of several patients hospitalized with anaphylactiod reactions to Feraheme. We are aware of one death that may or may not be directly related to Feraheme." On disclosure of this news, AMAG's stock fell over $7.00 per share to close at $38.12 per share.

The complaint further alleges that the Registration Statement failed to disclose that the effect of the Company's rebate program would be to front load sales into the fourth quarter causing sales to drop off after the Offering was completed. On this disclosure, AMAG's stock price once again declined, closing on March 1 at $34.17 per share down $4.02 from the previous day's closing price of $38.19.

If you are a current shareholder and purchased during company's secondary public offering ("Secondary Offering") on or about January 21, 2010. and would like to discuss your options of exercising your rights as a shareholder, please contact us.

Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.